by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Bio Technology : July 2009
Your GLP Preclinical Safety Testing Provider Genotoxicity Testing AMES, Micronucleus and Chromosome Aberration Mammalian Toxicity Testing Acute, Subacute, Subchronic, and Chronic Studies Custom Studies Tailored Pharmacology and Efficacy Models Cytotoxicity and Cell Viability Testing AusBioFEATURE Bioanalytical/ Analytical Services Pharmacokinetics & Toxicokinetic Studies Clinical Pathology Services Blood Chemistry, Haematology and Urinalysis Histology Services Specimen Handling, Tissue Cut-Up and Slide Preparation Vitamin D Assay Testing are composed of a small protein called beta-amyloid, which when it accumulates in high levels, is extremely toxic to brain cells. A Perth biotechnology company (Alzhyme) is developing novel treatments and early-stage diagnostics for Alzheimer’s disease, commercialising the research findings of Professor Ralph Martins. The company has developed a selection of potentially therapeutic peptides that specifically neutralise the damaging potential of the beta-amyloid protein. It is now widely accepted that it is the action of the beta-amyloid protein that leads to the production of the senile plaques in the brain is responsible for the destruction of brain cells and a deterioration of mental function. This has been called the “Amyloid Cascade Hypothesis” and there are now a number of companies trying to develop ‘anti-amyloid’ drugs. Current treatments on the market for Alzheimer’s disease are aimed at treating only the symptoms of the disease (e.g. drugs to improve the memory) and do not target the underlying cause of the disease. The latest research is unique in that it is focussing on a very early stage of the disease by targeting the effects of soluble oligomeric forms of beta-amyloid protein, well before the senile plaques are formed in the brain. Early intervention means less brain cells will die and progression of the disease may be halted. Dr Greg Thomas: email@example.com Volume 19 • Number 2 • July 2009 Australasian BioTechnology 29 RDDT Laboratories, a trading division of RMIT Drug Discovery Technologies Pty Ltd ACN: 123 380 110 Tel: +61 3 9925 7543 Fax: +61 3 9925 7020 E-mail: firstname.lastname@example.org Web: www.rddt.com.au